Cidara Therapeutics Inc (NASDAQ: CDTX) on Tuesday, soared 4.45% from the previous trading day, before settling in for the closing price of $48.3. Within the past 52 weeks, CDTX’s price has moved between $10.14 and $56.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1.30%. The company achieved an average annual earnings per share of 71.53%. With a float of $13.09 million, this company’s outstanding shares have now reached $22.12 million.
Let’s determine the extent of company efficiency that accounts for 38 employees. In terms of profitability, gross margin is 81.13%, operating margin of -35743.71%, and the pretax margin is -61454.97%.
Cidara Therapeutics Inc (CDTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cidara Therapeutics Inc is 40.83%, while institutional ownership is 47.21%. The most recent insider transaction that took place on Jun 26 ’25, was worth 99,999,988. In this transaction Director of this company bought 2,272,727 shares at a rate of $44.00, taking the stock ownership to the 3,365,523 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Director bought 2,270 for $21.71, making the entire transaction worth $49,281. This insider now owns 2,270 shares in total.
Cidara Therapeutics Inc (CDTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 71.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 36.71% during the next five years compared to 1.30% growth over the previous five years of trading.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Cidara Therapeutics Inc (CDTX) is currently performing well based on its current performance indicators. A quick ratio of 3.87 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3719.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -29.07, a number that is poised to hit -1.95 in the next quarter and is forecasted to reach -7.58 in one year’s time.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Looking closely at Cidara Therapeutics Inc (NASDAQ: CDTX), its last 5-days average volume was 0.87 million, which is a jump from its year-to-date volume of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 61.39%.
During the past 100 days, Cidara Therapeutics Inc’s (CDTX) raw stochastic average was set at 84.67%, which indicates a significant increase from 82.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 4.60 in the past 14 days, which was higher than the 2.07 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.26, while its 200-day Moving Average is $21.03. However, in the short run, Cidara Therapeutics Inc’s stock first resistance to watch stands at $52.11. Second resistance stands at $53.78. The third major resistance level sits at $56.90. If the price goes on to break the first support level at $47.33, it is likely to go to the next support level at $44.21. Now, if the price goes above the second support level, the third support stands at $42.54.
Cidara Therapeutics Inc (NASDAQ: CDTX) Key Stats
Market capitalization of the company is 1.12 billion based on 20,164K outstanding shares. Right now, sales total 1,280 K and income totals -169,830 K. The company made 0 K in profit during its latest quarter, and -23,480 K in sales during its previous quarter.
